Industry
Drug Manufacturers - General
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Loading...
Open
9.26
Mkt cap
7.4B
Volume
2M
High
9.94
P/E Ratio
36.54
52-wk high
12.15
Low
9.12
Div yield
N/A
52-wk low
5.30
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 4:17 pm
Portfolio Pulse from Benzinga Newsdesk
October 29, 2024 | 12:09 pm
Portfolio Pulse from Benzinga Newsdesk
October 22, 2024 | 12:12 pm
Portfolio Pulse from Benzinga Newsdesk
October 03, 2024 | 12:04 pm
Portfolio Pulse from Avi Kapoor
September 24, 2024 | 12:51 pm
Portfolio Pulse from Benzinga Newsdesk
August 29, 2024 | 4:22 pm
Portfolio Pulse from Lekha Gupta
August 25, 2024 | 8:45 pm
Portfolio Pulse from Avi Kapoor
August 22, 2024 | 3:17 pm
Portfolio Pulse from Benzinga Newsdesk
August 21, 2024 | 4:32 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.